Chemocentryx Piotroski F Score

CCXI -  USA Stock  

USD 25.26  1.12  4.64%

This module uses fundamental data of Chemocentryx to approximate its Piotroski F score. Chemocentryx F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Chemocentryx. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Chemocentryx financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Continue to Chemocentryx Altman Z Score, Chemocentryx Correlation, Chemocentryx Valuation, as well as analyze Chemocentryx Alpha and Beta and Chemocentryx Hype Analysis.

Chemocentryx Piotroski F Score 

 
Refresh
The current Total Debt is estimated to increase to about 78.3 M. The current Debt Current is estimated to increase to about 7.8 M. Chemocentryx Receivables Turnover is most likely to increase significantly in the upcoming years. The last year's value of Receivables Turnover was reported at 372.16. The current Accounts Payable Turnover is estimated to increase to 10.60, while Operating Margin is projected to decrease to (100.36) .
At this time, it appears that Chemocentryx's Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
3.0
Piotroski F Score - Frail
1
Current Return On Assets
Negative
2
Change in Return on Assets
Decreased
3
Cash Flow Return on Assets
Negative
4
Current Quality of Earnings (accrual)
Improving
5
Asset Turnover Growth
Increase
6
Current Ratio Change
Decrease
7
Long Term Debt Over Assets Change
Higher Leverage
8
Change In Outstending Shares
Decrease
9
Change in Gross Margin
No Change

Chemocentryx Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Chemocentryx is to make sure Chemocentryx is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Chemocentryx's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Chemocentryx's financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares64.9 M75.5 M
Fairly Down
Increasing
Slightly volatile
Weighted Average Shares Diluted65 M75.5 M
Fairly Down
Increasing
Slightly volatile
Net Cash Flow from Operations(75 M)(73 M)
Fairly Down
Decreasing
Slightly volatile
Total Assets643.8 M596.7 M
Significantly Up
Increasing
Slightly volatile
Total Liabilities122.3 M153.3 M
Significantly Down
Increasing
Slightly volatile
Current Assets547.9 M507.8 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities47.9 M59.3 M
Significantly Down
Increasing
Slightly volatile
Total Debt78.3 M72.5 M
Significantly Up
Increasing
Slightly volatile
Return on Average Assets(0.15)(0.14)
Notably Down
Increasing
Very volatile
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile
Asset Turnover0.210.17
Fairly Up
Increasing
Very volatile

Chemocentryx F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Chemocentryx's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Chemocentryx in a much-optimized way.

About Chemocentryx Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Book Value per Share

4.42Share
Chemocentryx Book Value per Share is most likely to drop in the upcoming years. The last year's value of Book Value per Share was reported at 5.28

Chemocentryx Current Valuation Drivers

We derive many important indicators used in calculating different scores of Chemocentryx from analyzing Chemocentryx's financial statements. These drivers represent accounts that assess Chemocentryx's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Chemocentryx's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee270.59 K(499.55 K)(676.7 K)(415.07 K)(477.33 K)(515.02 K)
Revenue Per Employee1.25 M564.14 K440.58 K486.57 K437.91 K425.21 K
Average Assets152.54 M190.61 M223.14 M447.82 M515 M555.65 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA18.28 M(36.23 M)(51.7 M)(49.95 M)(44.95 M)(48.5 M)
Earnings Before Interest Taxes and Depreciation Amortization USD18.28 M(36.23 M)(51.7 M)(49.95 M)(44.95 M)(48.5 M)
Earnings before Tax17.86 M(37.97 M)(55.49 M)(55.36 M)(49.82 M)(53.75 M)
Average Equity50.95 M22.66 M69.99 M317.93 M365.62 M394.49 M
Enterprise Value272.2 M541.85 M2.29 B4.29 B4.93 B5.32 B
Free Cash Flow4.16 M15.6 M(70.91 M)(96.55 M)(86.9 M)(89.18 M)
Invested Capital121.05 M110.52 M131.18 M498.12 M572.83 M618.06 M
Invested Capital Average87.97 M98.42 M135.44 M323.79 M372.36 M401.75 M
Market Capitalization290.16 M551.24 M2.3 B4.29 B4.93 B5.32 B
Tangible Asset Value189.33 M183.31 M209.08 M518.9 M596.73 M643.84 M
Working Capital146.89 M116.99 M115.28 M390.01 M448.51 M483.92 M

About Chemocentryx Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Chemocentryx's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Chemocentryx using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Chemocentryx based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The company is also developing CCX559, an orally-administered inhibitor for programmed death protein 1programmed death-ligand 1 for the treatment of various cancers and CCX507, an orally-administered inhibitor of the chemokine receptor CC9, which has completed Phase I clinical trial or the treatment of inflammatory bowel disease. In addition, it develops CCX587 for the treatment of TH17 driven diseases. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Chemocentryx without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Pattern Recognition Now

   

Pattern Recognition

Use different Pattern Recognition models to time the market across multiple global exchanges
All  Next Launch Module

Pair Trading with Chemocentryx

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Chemocentryx position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Chemocentryx will appreciate offsetting losses from the drop in the long position's value.

Chemocentryx Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Chemocentryx and Brickell Biotech. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to Chemocentryx Altman Z Score, Chemocentryx Correlation, Chemocentryx Valuation, as well as analyze Chemocentryx Alpha and Beta and Chemocentryx Hype Analysis. Note that the Chemocentryx information on this page should be used as a complementary analysis to other Chemocentryx's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Complementary Tools for Chemocentryx Stock analysis

When running Chemocentryx price analysis, check to measure Chemocentryx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chemocentryx is operating at the current time. Most of Chemocentryx's value examination focuses on studying past and present price action to predict the probability of Chemocentryx's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Chemocentryx's price. Additionally, you may evaluate how the addition of Chemocentryx to your portfolios can decrease your overall portfolio volatility.
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Is Chemocentryx's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chemocentryx. If investors know Chemocentryx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chemocentryx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Chemocentryx is measured differently than its book value, which is the value of Chemocentryx that is recorded on the company's balance sheet. Investors also form their own opinion of Chemocentryx's value that differs from its market value or its book value, called intrinsic value, which is Chemocentryx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chemocentryx's market value can be influenced by many factors that don't directly affect Chemocentryx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chemocentryx's value and its price as these two are different measures arrived at by different means. Investors typically determine Chemocentryx value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chemocentryx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.